

FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 5058 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008
L4 635 S L3/THU
L5 78047 S WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
L6 28 S L4 AND L5
L7 10 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'REGISTRY' ENTERED AT 17:54:11 ON 20 NOV 2008
L8 STRUCTURE UPLOADED
L9 2 S L8
L10 STRUCTURE UPLOADED
L11 1 S L10
L12 22 S L8 SSS FULL
L13 30 S L10 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:59:13 ON 20 NOV 2008
L14 2 S L12
L15 46 S L13
L16 364601 S SKIN OR TOPICAL OR COSMETIC
L17 11 S L15 AND L16
L18 8 S L17 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 NOV 2008 HIGHEST RN 1073427-79-8
DICTIONARY FILE UPDATES: 19 NOV 2008 HIGHEST RN 1073427-79-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10627994generic.str



```

chain nodes :
14 15 18 19 21 22 23 24 25 26 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
1-21 2-19 3-18 6-22 9-14 11-15 12-34 24-25 25-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13

exact/norm bonds :
1-21 2-19 3-18 6-22 7-11 8-13 9-14 11-12 11-15 12-13 12-34
exact bonds :
24-25 25-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

```

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,H

G2:H,Ph,[*1],[*2]

Connectivity :
 23:1 X maximum RC ring/chain
 Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 18:CLASS 19:CLASS 21:CLASS
 22:CLASS 23:CLASS 24:CLASS
 25:CLASS 26:CLASS 34:CLASS
 Generic attributes :
 23:
 Saturation : Saturated
 Element Count :
 Node 23: Limited
 C,C1-8

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 17:03:02 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 1117 TO ITERATE


100.0% PROCESSED 1117 ITERATIONS 50 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 20335 TO 24345
 PROJECTED ANSWERS: 4142 TO 6058

L2 50 SEA SSS SAM L1

=> d l2 scan


L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 4-Nonanone, 1-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)-2,2-
 dimethyl-
 MF C22 H30 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Decanone, 10-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-3-methyl-
MF C24 H34 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H22 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-2,2-
dimethyl-1-phenyl-
MF C24 H26 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full

FULL SEARCH INITIATED 17:03:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 22227 TO ITERATE

100.0% PROCESSED 22227 ITERATIONS

5058 ANSWERS

SEARCH TIME: 00.00.04

L3 5058 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2008 VOL 149 ISS 21

FILE LAST UPDATED: 19 Nov 2008 (20081119/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13/thu
      763 L3
      1070527 THU/RL
L4      635 L3/THU
          (L3 (L) THU/RL)

=> s wrinkle or (fine line) or cosmetic or photoaging
      8727 WRINKLE
      345102 FINE
      773780 LINE
      1078 FINE LINE
          (FINE(W)LINE)
      69383 COSMETIC
      1291 PHOTOAGING
L5      78047 WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
```

```
=> s 14 and 15
L6      28 L4 AND L5

=> s 16 and (PY<2004 or AY<2004 or PRY<2004)
      24012588 PY<2004
      4789993 AY<2004
      4261204 PRY<2004
L7      10 L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
```

```
=> d 17 1-10 ti abs bib
```

```
L7  ANSWER 1 OF 10  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI  Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
AB  The present invention relates to a foamable pharmaceutical carrier
    comprising a benefit agent, selected from the group consisting of a
    dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected
    from the group consisting of at least one surface-active agent; at least
    one polymeric agent and mixts. thereof; a solvent selected from the group
    consisting of water, a hydrophilic solvent, a hydrophobic solvent, a
    potent solvent, a polar solvent, a silicone, an emollient, and mixts.
    thereof, wherein the benefit agent, stabilizer and solvent are selected to
    provide a composition that is substantially resistant to aging and to phase
    separation and or can substantially stabilize other active ingredients. The
    invention further relates to a foamable composition further containing a
    liquefied
    hydrocarbon gas propellant. Thus, a foaming vehicle composition comprised (i)
    an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.00,
    oleyl alc. 20.00, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and
    stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me
    cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol
    17.70, and water 30.00%, resp.
```

```
AN  2008:226051  HCAPLUS <<LOGINID::20081120>>
DN  148:269446
```

```
TI  Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
IN  Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David
PA  Foamix Ltd., Israel
SO  U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.
    CODEN: USXXCO
```

```
DT  Patent
LA  English
```

```
FAN.CNT 30
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20080044444	A1	20080221	US 2007-825406	20070705 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--

WO 2004037225 A3 20041229

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050031547 A1 20050210 US 2004-835505 20040428 <--

US 20050069566 A1 20050331 US 2004-911367 20040804 <--

AU 2004313285 A1 20050929 AU 2004-313285 20041216 <--

US 20050232869 A1 20051020 US 2005-78902 20050311 <--

ZA 2005003298 A 20060830 ZA 2005-3298 20050425 <--

US 20060140984 A1 20060629 US 2005-532618 20051222 <--

AU 2006201878 A1 20070927 AU 2006-201878 20060504 <--

US 20070280891 A1 20071206 US 2006-645444 20061226 <--

US 20070292461 A1 20071220 US 2007-653205 20070112 <--

US 20070253911 A1 20071101 US 2007-717897 20070313 <--

WO 2008038147 A2 20080403 WO 2007-IB3759 20070705

WO 2008038147 A3 20081016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080050317 A1 20080228 US 2007-894668 20070820 <--

PRAI IL 2002-152486 A 20021025 <--

US 2002-429546P P 20021129 <--

US 2003-492385P P 20030804 <--

WO 2003-IB5527 W 20031024 <--

US 2003-530015P P 20031216 <--

US 2004-835505 A2 20040428

US 2004-911367 A2 20040804

US 2005-78902 A2 20050311

US 2005-532618 A2 20051222

US 2006-818634P P 20060705

US 2007-653205 A2 20070112

US 2007-717897 A2 20070313

US 2005-679020P P 20050509

US 2006-781868P P 20060313

US 2006-784793P P 20060321

US 2006-430599 A2 20060509

US 2007-897638P P 20070126

US 2007-899176P P 20070202

L7 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Film forming foamable pharmaceutical and cosmetic compositions and cosmetic and therapeutic uses thereof

AB The present invention provides a film-forming foamable cosmetic or pharmaceutical vehicle, and cosmetic and/or pharmaceutical compns. thereof. Specifically, the foamable composition, includes (1) about 6%

to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alc. free and is used in treating, alleviating or preventing a disorder.

AN 2006:890398 HCAPLUS <<LOGINID::20081120>>
 DN 145:298800
 TI Film forming foamable pharmaceutical and cosmetic compositions
 and cosmetic and therapeutic uses thereof
 IN Tamarkin, Dov; Friedman, Doron; Eini, Meir
 PA Foamix Ltd., Israel
 SO U.S. Pat. Appl. Publ., 20pp., Cont.-in-part of U.S. Ser. No. 922,358.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 30

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060193789	A1	20060831	US 2006-337747	20060123 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050069566	A1	20050331	US 2004-911367	20040804 <--
	US 20050074414	A1	20050407	US 2004-922358	20040820 <--
	ZA 2005003298	A	20060830	ZA 2005-3298	20050425 <--
	AU 2006201878	A1	20070927	AU 2006-201878	20060504 <--
PRAI	IL 2002-152486	A	20021025	<--	
	US 2002-429546P	P	20021129	<--	
	US 2003-492385P	P	20030804	<--	
	US 2003-497648P	P	20030825	<--	
	WO 2003-IB5527	A2	20031024	<--	
	US 2004-911367	A2	20040804		
	US 2004-922358	A2	20040820		

L7 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Topical treatment of dermatological disorders associated with reactive or
 dilated blood vessels
 AB The invention provides a method of topically treating a dermatol.
 disorder. The method includes topically applying a therapeutically
 effective amount of a cosmetic or dermatol. composition to an affected
 area of the skin. The composition includes at least one compound that is (i) a
 polyhydroxy-alldonic acid, (ii) a polyhydroxy-alldonic lactone, (iii) a
 polyhydroxy-allduronic acid, (iv) a polyhydroxy-allduronic lactone, (v) a
 polyhydroxy-alldaric acid; (vi) a polyhydroxy-alldaric lactone, and (vii) an
 organic acid lactone having two or more hydroxyl or ketohydroxyl groups. The
 dermatol. disorder treated is one associated with reactive or dilated blood
 vessels. Also included in the invention are methods of treating dermatol.
 disorders associated with reactive blood vessels that include topical
 application of a therapeutically effective amount of a composition
 AN 2004:934335 HCAPLUS <<LOGINID::20081120>>
 DN 141:388761

TI Topical treatment of dermatological disorders associated with reactive or
dilated blood vessels
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040220259	A1	20041104	US 2004-817479	20040402 <--
	WO 2004093722	A2	20041104	WO 2004-US10454	20040405 <--
	WO 2004093722	A3	20050331		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,
BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, EG,
ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL,
IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ,
LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX,
MX, MZ, MZ, NA

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

PRAI US 2003-460322P P 20030404 <--
US 2004-817479 A 20040402

OS MARPAT 141:388761

L7 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Acidic drug complexes for improved bioavailability and delivery

AB Embodiments of the invention relate to a composition, a process of making the
composition, and to the use of the composition The compns. include a mol.
complex

formed between an acidic pharmaceutical drug and at least one functional
substance. The compns. provide improved bioavailability and improved
delivery of the drug into the cutaneous tissues. For example,
methotrexate complex with L-lysine was found to have less skin irritation
when applying topically to treat psoriasis on the forearm.

AN 2004:799452 HCAPLUS <<LOGINID::20081120>>

DN 141:301435

TI Acidic drug complexes for improved bioavailability and delivery

IN Yu, Ruey J.; Van Scott, Eugene J.

PA USA

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082628	A2	20040930	WO 2004-US8112	20040317 <--
	WO 2004082628	A3	20041119		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 20040220264 A1 20041104 US 2004-801134 20040316 <--
AU 2004222305 A1 20040930 AU 2004-222305 20040317 <--
CA 2519126 A1 20040930 CA 2004-2519126 20040317 <--
EP 1603549 A2 20051214 EP 2004-757550 20040317 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-454631P P 20030317 <--
US 2004-801134 A 20040316
WO 2004-US8112 A 20040317

OS MARPAT 141:301435

L7 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Non-amphoteric glutathione derivative compositions for topical application

AB Topical compns. and methods including non-amphoteric derivs. of
glutathione, for example, N-acyl-glutathiones, N-acyl-glutathione amides,
and N-acyl-glutathione esters are disclosed for use in the treatment and
prevention of cosmetic conditions and dermatol. disorders, are
disclosed. The non-amphoteric glutathione derivs. may have the structure
of (I): R' -COCHNH (R2) H2CH2CONHCH(CH2SR3) CONHCH2 CO-R' wherein R' is
independently selected from -OH, -NH2, -NHNH2, an alkoxyl group, an
aralkoxyl group, and an aryloxyl group and R2 and R3 are each
independently selected from a hydrogen atom or an acyl group, but if at
least one R' is -OH, -NH2, or -NHNH2, then R2 is an acyl group.

AN 2004:100971 HCAPLUS <<LOGINID::20081120>>

DN 140:169245

TI Non-amphoteric glutathione derivative compositions for topical application

IN Yu, Ruey J.; Van Scott, Eugene J.

PA USA

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004010968	A1	20040205	WO 2003-US24048	20030731 <--
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	US 20040147452	A1	20040729	US 2003-626158	20030724 <--
	AU 2003257105	A1	20040216	AU 2003-257105	20030731 <--
PRAI	US 2002-400252P	P	20020731	<--	
	US 2003-626158	A	20030724	<--	
	WO 2003-US24048	W	20030731	<--	

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI N-Acetyl cysteine and its topical use

AB Methods to alleviate or improve various cosmetic conditions and dermatol. disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors using compns. comprising N-acetyl-cysteine (isomeric or non-isomeric forms) and/or free acid, salt, lactone, amide or ester forms of N-acetyl-cysteine are described. The methods provided may also comprise application of a composition further containing

various cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.

AN 2003:971738 HCAPLUS <<LOGINID::20081120>>

DN 140:23273

TI N-Acetyl cysteine and its topical use

IN Yu, Ruey J.; Van Scott, Eugene J.

PA USA

SO U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Pat. Appl. 2003 198,656.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20030229141	A1	20031211	US 2003-462885	20030617 <--
	US 6159485	A	20001212	US 1999-227213	19990108 <--
	EP 1570840	A2	20050907	EP 2004-29094	20000107 <--
	EP 1570840	A3	20051116		
	R: DE, ES, FR, GB, IT				
	EP 1639994	A2	20060329	EP 2005-18302	20000107 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6524593	B1	20030225	US 2000-560901	20000428 <--
	US 20030198656	A1	20031023	US 2003-371504	20030221 <--
	US 6808716	B2	20041026		
PRAI	US 1999-227213	A1	19990108	<--	
	US 2000-560901	A2	20000428	<--	
	US 2003-371504	A2	20030221	<--	
	EP 2000-902347	A3	20000107	<--	

L7 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Urea compositions for the treatment of skin disorders

AB The invention is directed to compns., methods of making the compns., and methods of treating cosmetic and dermatol. disorders with a composition that includes a mol. complex between urea and a functional substance that has at least one hydroxyl group and one carboxyl group either as a free acid, a salt, an amide or a lactone. The compns. are stable when compared to conventional urea-containing compns., and provide controlled-release of the urea. For example, urea 15 g was dissolved in 27 mL water and galacturonic acid 8 g was slowly added to form a mol. complex until the solution changed pH from 7.4 to 1.9. A clear solution containing

the mol. complex was mixed with a hydrophilic ointment.

AN 2003:836770 HCAPLUS <<LOGINID::20081120>>

DN 139:341739

TI Urea compositions for the treatment of skin disorders

IN Yu, Ruey J.; Van Scott, Eugene J.

PA USA

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086291	A2	20031023	WO 2003-US10823	20030409 <--
	WO 2003086291	A3	20040226		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2481702	A1	20031023	CA 2003-2481702	20030409 <--
	AU 2003220691	A1	20031027	AU 2003-220691	20030409 <--
	US 20040033963	A1	20040219	US 2003-409684	20030409 <--
	EP 1492486	A2	20050105	EP 2003-717012	20030409 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-371157P	P	20020410	<--	
	WO 2003-US10823	W	20030409	<--	

L7 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod

AB Background: Treatment of cutaneous leishmaniasis can be painful and protracted and cosmetic results are often unsatisfying. The immune modulator imiquimod has been reported to be suitable for the treatment of a variety of infectious skin diseases and neoplasias. Objective: We investigated the efficacy of topical application of imiquimod in the treatment of old world leishmaniasis in a placebo-controlled prospective study. Methods: Twelve patients were treated with imiquimod cream using a standard protocol, i.e. topical application three times a week, and a further three served as control group. Results: Lesions of cutaneous leishmaniasis regressed within the first 2-4 wk in 10 of the 12 patients, whereas in two patients no change was observed. However, after 8 wk all lesions showed progression. Conclusion: Our results thus demonstrate that topical application of imiquimod alone is ineffective in treating old world cutaneous leishmaniasis. Further studies are required to demonstrate a possible benefit of imiquimod in combination with other, preferably orally administered medicines.

AN 2003:641685 HCAPLUS <<LOGINID::20081120>>

DN 139:239754

TI Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod

AU Seeberger, Josef; Daoud, Saleh; Pammer, Johannes

CS Department of Dermatology and Venereology, Faculty of Medicine, University of Damascus, Syria

SO International Journal of Dermatology (2003), 42(7), 576-579

CODEN: IJDEBB; ISSN: 0011-9059

PB Blackwell Publishing Ltd.

DT Journal

LA English

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Selective enzyme treatment of skin conditions

AB A method of treating skin conditions by providing compns. containing enzymes to selectively remove specific layers of skin. The depth of skin removed (i.e., vertical surface treated) is regulated by the type and concentration of enzyme or enzymes in the composition. The surface area of skin removed (i.e., radial surface treated) is regulated by the area of topical application. Conditions treatable by the method include, but are not limited to, age-related conditions such as lines and wrinkles, infections, pigmentary disorders, follicular disorders such as acne, and hyperkeratotic disorders such as warts. The method and composition of the invention thus achieves the specificity and efficacy of more invasive methods such as surgery, while providing a composition that may be topically applied and is easy to use.

AN 2003:97805 HCAPLUS <<LOGINID::20081120>>

DN 138:147770

TI Selective enzyme treatment of skin conditions

IN Fein, Howard

PA USA

SO U.S. Pat. Appl. Publ., 13 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20030026794	A1	20030206	US 2001-919102	20010731 <--
PRAI	US 2001-919102		20010731	<--	

L7 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use

AB Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepared by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.

AN 2001:31287 HCAPLUS <<LOGINID::20081120>>

DN 134:105670

TI Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use

IN Yu, Ruey J.; Van Scott, Eugene J.

PA USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001001932	A2	20010111	WO 2000-US16301	20000628 <--
	WO 2001001932	A3	20010517		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6335023	B1	20020101	US 2000-487228	20000119 <--
CA 2373852	A1	20010111	CA 2000-2373852	20000628 <--
BR 2000011640	A	20020514	BR 2000-11640	20000628 <--
EP 1227820	A2	20020807	EP 2000-950220	20000628 <--
EP 1227820	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503436	T	20030128	JP 2001-507430	20000628 <--
AU 775620	B2	20040805	AU 2000-63353	20000628 <--
CN 1635864	A	20050706	CN 2000-809776	20000628 <--
AT 323498	T	20060515	AT 2000-950220	20000628 <--
EP 1685843	A1	20060802	EP 2006-6895	20000628 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1227820	T	20060831	PT 2000-950220	20000628 <--
ES 2262529	T3	20061201	ES 2000-950220	20000628 <--
US 20020028227	A1	20020307	US 2001-987023	20011113 <--
US 6740327	B2	20040525		
MX 2001PA13042	A	20030820	MX 2001-PA13042	20011217 <--
HK 1048764	A1	20060915	HK 2003-100874	20030206 <--
US 7452545	B2	20081118	US 2004-811998	20040330 <--
US 20040180854	A1	20040916		
AU 2004212601	A1	20041014	AU 2004-212601	20040920 <--
AU 2004212601	B2	20070614		
JP 2005232180	A	20050902	JP 2005-74658	20050316 <--
US 20080090772	A1	20080417	US 2007-872459	20071015 <--
PRAI US 1999-141264P	P	19990630	<--	
US 2000-487228	A	20000119	<--	
AU 2000-63353	A	20000628	<--	
EP 2000-950220	A3	20000628	<--	
JP 2001-507430	A3	20000628	<--	
WO 2000-US16301	W	20000628	<--	
US 2001-987023	A1	20011113	<--	
US 2004-811998	A3	20040330		
OS MARPAT 134:105670				

=> d his

(FILE 'HOME' ENTERED AT 17:02:02 ON 20 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 5058 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008

L4 635 S L3/THU
L5 78047 S WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
L6 28 S L4 AND L5
L7 10 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> log hold

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST	34.48	213.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:04:32 ON 20 NOV 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 17:53:54 ON 20 NOV 2008
FILE 'HCAPLUS' ENTERED AT 17:53:54 ON 20 NOV 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	34.48	213.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

=> file registry

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	34.48	213.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.00	-8.00

FILE 'REGISTRY' ENTERED AT 17:54:11 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 NOV 2008 HIGHEST RN 1073427-79-8
DICTIONARY FILE UPDATES: 19 NOV 2008 HIGHEST RN 1073427-79-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10627994claim33.str



```
chain nodes :
14 15 16 17 19 20 21 22 24 25 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 26 27 28 29 30 31
chain bonds :
1-19 2-17 3-16 6-20 9-14 11-15 12-24 15-25 21-22 25-26 29-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
26-27 26-31 27-28 28-29 29-30 30-31
exact/norm bonds :
7-11 8-13 9-14 11-12 12-13 26-27 26-31 27-28 28-29 29-30 29-33 30-31

exact bonds :
1-19 2-17 3-16 6-20 11-15 12-24 15-25 21-22 25-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
```

G2:H,n-Bu,C(O)CH3, [*1]

G3:H,Cl,PhO,NH2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS
24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 33:CLASS

L8 STRUCTURE UPLOADED

=> s 18

SAMPLE SEARCH INITIATED 17:54:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 128 TO ITERATE

100.0% PROCESSED 128 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1882 TO 3238

PROJECTED ANSWERS: 2 TO 124


L9 2 SEA SSS SAM L8

=> d 19 scan

L9 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Ethanone, 1-[4-[2-(4-phenoxy-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-1-piperidinyl]-


MF C25 H26 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Imidazo[4,5-c]quinolin-4-amine, 1-[2-(4-piperidinyl)ethyl]-
MF C17 H21 N5
CI COM





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\STNEXP\Queries\10627994claim34.str



```

chain nodes :
14 15 16 18 19 20 27 29 30 31 32 33 34 35 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 21 22 23 24 25
chain bonds :
1-18 2-16 3-15 6-19 9-14 11-29 12-20 14-30 14-38 22-27 31-32 32-33 32-35
33-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
21-22 21-25 22-23 23-24 24-25
exact/norm bonds :
7-11 8-13 9-14 11-12 12-13 12-20 14-38 21-22 21-25 22-23 23-24 24-25

exact bonds :
1-18 2-16 3-15 6-19 11-29 14-30 22-27 31-32 32-33 32-35 33-34
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

```

G1:H,Ph, [*1]

G2:H,Ph, [*1], [*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 18:CLASS 19:CLASS
20:CLASS 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 27:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS
33:CLASS 34:CLASS
35:CLASS 38:CLASS

L10 STRUCTURE UPLOADED

=> s l10

SAMPLE SEARCH INITIATED 17:55:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1200 TO ITERATE

100.0% PROCESSED 1200 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 21922 TO 26078

PROJECTED ANSWERS: 1 TO 80

L11 1 SEA SSS SAM L10

=> log holds

'HOLS' IS NOT VALID HERE

For an explanation, enter "HELP LOGOFF".

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.92	214.43

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.00

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:55:38 ON 20 NOV 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 17:58:38 ON 20 NOV 2008

FILE 'REGISTRY' ENTERED AT 17:58:38 ON 20 NOV 2008

COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	214.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

=> d his

(FILE 'HOME' ENTERED AT 17:02:02 ON 20 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:02:21 ON 20 NOV 2008

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 5058 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:03:34 ON 20 NOV 2008


L4 635 S L3/THU
L5 78047 S WRINKLE OR (FINE LINE) OR COSMETIC OR PHOTOAGING
L6 28 S L4 AND L5
L7 10 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'REGISTRY' ENTERED AT 17:54:11 ON 20 NOV 2008

L8 STRUCTURE UPLOADED
L9 2 S L8
L10 STRUCTURE UPLOADED
L11 1 S L10

=> d l11 scan

L11 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[4,5-c]quinolin-4-amine
MF C10 H8 N4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l8 sss full

FULL SEARCH INITIATED 17:58:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2416 TO ITERATE

100.0% PROCESSED 2416 ITERATIONS
SEARCH TIME: 00.00.01

22 ANSWERS

L12 22 SEA SSS FUL L8

=> s l10 sss full
FULL SEARCH INITIATED 17:59:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 23862 TO ITERATE

100.0% PROCESSED 23862 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.02

L13 30 SEA SSS FUL L10

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	357.64	571.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'HCAPLUS' ENTERED AT 17:59:13 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 19 Nov 2008 (20081119/ED)

HCAPlus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12
L14 2 L12

=> s l13
L15 46 L13

=> d l14 1-2 ti abs bib

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
TI 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF- α
suppressors: synthesis and structure-activity relationship of 1-, 2-and
4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines
AB Structural modification of imiquimod, which is known as an

interferon- α (IFN- α) inducer, for the aim of finding a novel and small-mol. tumor necrosis factor- α (TNF- α) suppressor and structure-activity relationship (SAR) are described. Structural modification of a imiquimod analog, 4-amino-1-2-(1-benzyl-4-piperidyl)ethyl-1H-imidazo[4,5-c]quinoline, which had moderate TNF- α suppressing activity without IFN- α inducing activity, led to a finding of 4-chloro-2-phenyl-1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline with potent TNF- α suppressing activity. The relation between conformational direction of 2-(4-piperidyl)ethyl group at position 1 and TNF- α suppressing activity is also demonstrated by NMR.

AN 2003:393700 HCAPLUS <<LOGINID::20081120>>

DN 139:261235

TI 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF- α suppressors: synthesis and structure-activity relationship of 1-, 2-and 4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines

AU Izumi, Tomoyuki; Sakaguchi, Jun; Takeshita, Makoto; Tawara, Harumi; Kato, Ken-Ichi; Dose, Hitomi; Tsujino, Tomomi; Watanabe, Yoshinari; Kato, Hideo

CS R&D Headquarters, Research Division, Hokuriku Seiyaku Co., Ltd., 37-1-1, Inokuchi, Katsuyama, Fukui, 911-8555, Japan

SO Bioorganic & Medicinal Chemistry (2003), 11(12), 2541-2550
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English


OS CASREACT 139:261235

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of imidazopyridine derivatives as TNF and IL-1 production inhibitors

GI



AB The title compds. I [A1 = (CH₂)_m; R1 is hydrogen, hydroxyl, alkyl, cycloalkyl, styryl or aryl; R2 is hydrogen, alkyl, halogeno, hydroxyl, amino, cyclic amino or phenoxy; ring A is an optionally substituted homocycle or heterocycle; R3 is a saturated nitrogenous heterocyclic group; and m is an integer of 0 to 3] are prepared In an in vitro test using cells, the title compound II.CF₃CO₂H at 0.001 μ mol gave 79% inhibition of TNF- α production

AN 2000:133679 HCAPLUS <<LOGINID::20081120>>

DN 132:180573

TI Preparation of imidazopyridine derivatives as TNF and IL-1 production inhibitors

IN Kato, Hideo; Sakaguchi, Jun; Aoyama, Makoto; Izumi, Tomoyuki; Kato,
Ken-ichi
PA Hokuriku Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000009506	A1	20000224	WO 1999-JP4381	19990812
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2000119271	A	20000425	JP 1999-216125	19990730
	TW 533209	B	20030521	TW 1999-88113701	19990811
	CA 2339562	A1	20000224	CA 1999-2339562	19990812
	AU 9951974	A	20000306	AU 1999-51974	19990812
	AU 744388	B2	20020221		
	TR 200100439	T2	20010521	TR 2001-439	19990812
	EP 1104764	A1	20010606	EP 1999-937053	19990812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 2001003406	A2	20020228	HU 2001-3406	19990812
	HU 2001003406	A3	20021128		
	BR 9914306	A	20020521	BR 1999-14306	19990812
	NZ 509939	A	20020828	NZ 1999-509939	19990812
	CZ 292544	B6	20031015	CZ 2001-503	19990812
	MX 2001PA01378	A	20020327	MX 2001-PA1378	20010206
	NO 2001000676	A	20010410	NO 2001-676	20010209
	IN 2001CN00217	A	20050304	IN 2001-CN217	20010214
	BG 105271	A	20011130	BG 2001-105271	20010219
	ZA 2001001452	A	20010917	ZA 2001-1452	20010221
	HR 2001000144	A1	20020430	HR 2001-144	20010228
	US 6518265	B1	20030211	US 2001-744959	20010502
PRAI	JP 1998-241062	A	19980812		
	JP 1999-216125	A	19990730		
	WO 1999-JP4381	W	19990812		

OS MARPAT 132:180573

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s skin or topical or cosmetic

290893 SKIN

53553 TOPICAL

69383 COSMETIC

L16 364601 SKIN OR TOPICAL OR COSMETIC

=> s l15 and l16

L17 11 L15 AND L16

=> s l17 and (PY<2004 or AY<2004 or PRY<2004)

24012588 PY<2004

4789993 AY<2004

4261204 PRY<2004

L18 8 L17 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> d 118 1-8 ti abs bib

L18 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Imidazoquinoline adjuvants for vaccines

AB The author discloses that topical administration of imidazoquinolines (e.g., imiquimod) enhances the T-cell response to genetic immunization. In one example, the interferon- γ -producing CD8+ T-cell response to HBsAg was enhanced by the topical administration of Aldara.

AN 2006:388764 HCAPLUS <<LOGINID::20081120>>

DN 144:410797

TI Imidazoquinoline adjuvants for vaccines

IN Braun, Ralph Patrick

PA Powdermed Limited, USA

SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 102,615.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060088542	A1	20060427	US 2004-508143	20041118 <--
	US 20030185835	A1	20031002	US 2002-102615	20020319 <--
	WO 2003080114	A2	20031002	WO 2003-GB1203	20030319 <--
	WO 2003080114	A3	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-102615	B2	20020319	<--	
	US 2002-366057P	P	20020319	<--	
	WO 2003-GB1203	W	20030319	<--	
OS	MARPAT 144:410797				

L18 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Adjuvant compositions and particle-delivered codon-optimized DNA vaccines encoding HIV antigens, useful in prophylaxis and treatment of HIV infections

AB The present invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The invention in particular relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV infections, more particularly when administered by particle mediated delivery. The examples disclose the use of imiquimod, in the form of Aldara cream, to enhance immune response to DNA vaccines encoding viral antigens, epitopes and fusions thereof. Also disclosed is the optimization of the viral coding sequences to more closely resemble the codon usage of highly expressed human genes. Methods used include gold particle-mediated immunization of plasmid DNA using "gene gun" DNA cartridges.

AN 2005:1261796 HCAPLUS <<LOGINID::20081120>>

DN 144:21828

TI Adjuvant compositions and particle-delivered codon-optimized DNA vaccines encoding HIV antigens, useful in prophylaxis and treatment of HIV

infections

IN Braun, Ralph Patrick; Thomsen, Lindy; Van-Wely, Catherine; Ertl, Peter
PA Powdermed Limited, UK; Glaxo Group Limited
SO U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 102,622.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050266024	A1	20051201	US 2005-507928	20050509 <--
	US 20030190308	A1	20031009	US 2002-102622	20020319 <--
	WO 2003080112	A2	20031002	WO 2003-GB1213	20030319 <--
	WO 2003080112	A3	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050256070	A1	20051117	US 2005-29465	20050106 <--
PRAI	US 2002-102622	A2	20020319	<--	
	US 2002-366058P	P	20020319	<--	
	WO 2003-GB1213	W	20030319	<--	
OS	MARPAT 144:21828				

L18 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Immunostimulatory combinations and treatments

AB The present invention provides immunostimulatory combinations and methods. Generally, the immunostimulatory combinations include a topical formulation of an immuno response modifier (IRM) compound and a pharmaceutical composition. Generally, the methods include administering (a) a topical formulation of an IRM compound, and (b) a pharmaceutical composition to an administration site of a subject. A topical cream contained 2-propylthiazolo[4,5-c]quinolin-4-amine 1.00, isostearic acid 5.00, iso-Pr myristate 10.00, Poloxamer-188, 2.50, edetate disodium 0.05, Carbomer-974 1.50, propylene glycol 15.00, propylparaben 0.10, methylparaben 0.20, purified water 63.95, and 20% NaOH 0.70%.

AN 2005:177852 HCAPLUS <<LOGINID::20081120>>

DN 142:266767

TI Immunostimulatory combinations and treatments

IN Kedl, Ross M.; Tomai, Mark A.; Vasilakos, John P.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005018574	A2	20050303	WO 2004-US27712	20040825 <--
	WO 2005018574	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004266162 A1 20050303 AU 2004-266162 20040825 <--
CA 2551075 A1 20050303 CA 2004-2551075 20040825 <--
AU 2004268616 A1 20050310 AU 2004-268616 20040825 <--
CA 2536249 A1 20050310 CA 2004-2536249 20040825 <--
WO 2005020912 A2 20050310 WO 2004-US27633 20040825 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1658035 A2 20060524 EP 2004-782185 20040825 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

EP 1660122 A2 20060531 EP 2004-801917 20040825 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007503268 T 20070222 JP 2006-524827 20040825 <--
JP 2007504145 T 20070301 JP 2006-524843 20040825 <--

PRAI US 2003-497628P P 20030825 <--
US 2003-524213P P 20031121 <--
WO 2004-US27633 W 20040825
WO 2004-US27712 W 20040825

L18 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Compositions and methods for induction of opioid receptors, and
therapeutic use

AB The invention provides compns. and method for increasing expression of
opioid receptors. Generally, the compns. include an opioid
receptor-inducing compound (e.g. an imidazoquinoline amine compound) and,
optionally, an opioid receptor ligand. Generally, the methods include
contacting a cell with an amount of an opioid receptor-inducing compound
effective for inducing expression of the opioid receptor and, optionally,
contacting the cell with an opioid receptor ligand. The methods of the
invention may be used e.g. to reduce the effects of tissue damage.

AN 2004:905622 HCAPLUS <<LOGINID::20081120>>

DN 141:374755

TI Compositions and methods for induction of opioid receptors, and
therapeutic use

IN Birmachu, Woubalem M. R.; Slade, Herbert B.; Stolpa, John C.; Urosevic,
Mirjana

PA 3M Innovative Properties Company, USA

SO U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040214851	A1	20041028	US 2004-832737	20040427 <--

WO 2004096144 A2 20041111 WO 2004-US12897 20040427 <--
 WO 2004096144 A3 20050909
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 EP 1617845 A2 20060125 EP 2004-760404 20040427 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 PRAI US 2003-466227P P 20030428 <--
 WO 2004-US12897 W 20040427

L18 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Administration of dendritic cells partially matured in vitro for the
 treatment of tumors

AB The disclosed invention provides populations of cells comprising partially
 matured dendritic cells that can be used for administration to individuals
 having a tumor. Partially matured dendritic cells, contacted with a
 dendritic cell maturation agent (preferably Mycobacterium BCG and
 interferon γ) for about 1-10 h, or more, efficiently take up and
 process tumor antigens in the area of the tumor site, complete maturation,
 and can subsequently migrate to the lymph nodes of a treated individual.
 Once in the lymph node the now fully mature antigen-presenting dendritic
 cells secrete the appropriate cytokines (e.g., TNF α and IL-12) and
 contact T cells inducing a substantial anti-tumor immune response. In a
 mouse model with xenografted human CT26 colon carcinoma partially matured
 dendritic cells had a considerable antitumor effect. A patient diagnosed
 with a solid tumor was treated with chemotherapy, radiation therapy,
 cryotherapy, or brachytherapy and subsequently with partially matured
 dendritic cells administered intratumorally. Following treatment, the
 tumor was resolved and the patient was protected from tumor recurrence.

AN 2004:515648 HCAPLUS <<LOGINID::20081120>>

DN 141:52876

TI Administration of dendritic cells partially matured in vitro for the
 treatment of tumors

IN Bosch, Marnix L.

PA Northwest Biotherapeutics, Inc., USA

SO PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053072	A2	20040624	WO 2003-US38672	20031205 <--
	WO 2004053072	A3	20050616		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			

	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,			
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA	2509058	A1	20040624	CA 2003-2509058 20031205 <--
AU	2003293411	A1	20040630	AU 2003-293411 20031205 <--
EP	1567155	A2	20050831	EP 2003-790358 20031205 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR	2003017064	A	20051025	BR 2003-17064 20031205 <--
CN	1738619	A	20060222	CN 2003-80108975 20031205 <--
JP	2006510667	T	20060330	JP 2004-559310 20031205 <--
MX	2005PA06042	A	20050921	MX 2005-PA6042 20050606 <--
US	20060057120	A1	20060316	US 2005-538226 20050606 <--
IN	2005CN01136	A	20070824	IN 2005-CN1136 20050606 <--
PRAI	US 2002-431267P	P	20021206	<--
	WO 2003-US38672	W	20031205	<--

L18 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Immune adjuvant comprising imidazoquinoline amine or imidazopyridine amine for nucleic acid vaccine delivery

AB The invention relates to the fields of vaccines, vaccine adjuvants, mol. biol. and immunol., and generally relates to adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The adjuvant compound is an imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- or oxazolo-quinolinamine or pyridinamines, imidazonaphthyridine or tetrahydroimidazonaphthyridine amine; especially imidazoquinoline, imiquimod or resiquimod. The vaccine is DNA vaccine comprising gene encoding HBsAg, HSV-2 antigen (e.g. gD or gB protein), cholera toxin or HSP70. The vaccine compns. are administered topically or transdermally in the forms of particles or creams.

AN 2003:777630 HCAPLUS <<LOGINID::20081120>>

DN 139:291106

TI Immune adjuvant comprising imidazoquinoline amine or imidazopyridine amine for nucleic acid vaccine delivery

IN Braun, Ralph Patrick

PA Powderject Research Limited, UK

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003080114	A2	20031002	WO 2003-GB1203	20030319 <--
	WO 2003080114	A3	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	20030185835	A1	20031002	US 2002-102615	20020319 <--
CA	2484049	A1	20031002	CA 2003-2484049	20030319 <--
AU	2003216851	A1	20031008	AU 2003-216851	20030319 <--
AU	2003216851	B2	20080417		

EP 1487485 A2 20041222 EP 2003-712390 20030319 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005526793 T 20050908 JP 2003-577939 20030319 <--
 US 20060088542 A1 20060427 US 2004-508143 20041118 <--
 PRAI US 2002-102615 A 20020319 <--
 US 2002-366057P P 20020319 <--
 WO 2003-GB1203 W 20030319 <--
 OS MARPAT 139:291106

L18 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Immune adjuvant comprising imidazoquinoline or imidazopyridine amines for DNA vaccines

AB The invention relates to certain adjuvant compns., and to vaccine and/or nucleic acid immunization strategies employing such compns. The invention in particular relates to DNA vaccines that are useful in the prophylaxis and treatment of HIV infections, more particularly when administered by particle mediated delivery. The adjuvant uses imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazolo- and oxazoloquinolinamine or pyridinamine, imidazonaphthyridine or tetrahydronaphthyridine amine to enhance immune response.

AN 2003:777628 HCAPLUS <<LOGINID::20081120>>

DN 139:291105

TI Immune adjuvant comprising imidazoquinoline or imidazopyridine amines for DNA vaccines

IN Braun, Ralph Patrick; Thomsen, Lindy; Van-Wely, Catherine; Ertl, Peter

PA Powderject Research Limited, UK; Glaxo Group Limited

SO PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080112	A2	20031002	WO 2003-GB1213	20030319 <--
	WO 2003080112	A3	20031106		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20030190308	A1	20031009	US 2002-102622	20020319 <--
	CA 2484044	A1	20031002	CA 2003-2484044	20030319 <--
	AU 2003216852	A1	20031008	AU 2003-216852	20030319 <--
	AU 2003216852	B2	20080911		
	EP 1487486	A2	20041222	EP 2003-712391	20030319 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005533752	T	20051110	JP 2003-577938	20030319 <--
	US 20050256070	A1	20051117	US 2005-29465	20050106 <--
	US 20050266024	A1	20051201	US 2005-507928	20050509 <--
PRAI	US 2002-102622	A	20020319	<--	
	US 2002-366058P	P	20020319	<--	
	WO 2003-GB1213	W	20030319	<--	
OS	MARPAT 139:291105				

L18 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Use of imidazoquinolinamines as adjuvants in DNA vaccination
 AB The present invention relates to the use of a
 1H-imidazo[4,5-c]quinolin-4-amine derivative as an adjuvant for use with
 nucleic acid vaccination. The vaccine comprises the adjuvant and a
 nucleotide sequence encoding an antigen associated with a disease. The
 diseases can include infection, cancer, allergy, and autoimmunity.
 AN 2002:240588 HCAPLUS <<LOGINID::20081120>>
 DN 136:261816
 TI Use of imidazoquinolinamines as adjuvants in DNA vaccination
 IN Thomsen, Lindy Louise; Tite, John Philip; Topley, Peter
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024225	A1	20020328	WO 2001-GB4207	20010920 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2422863	A1	20020328	CA 2001-2422863	20010920 <--
	AU 2001087908	A	20020402	AU 2001-87908	20010920 <--
	EP 1318835	A1	20030618	EP 2001-967535	20010920 <--
	EP 1318835	B1	20080716		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013982	A	20030819	BR 2001-13982	20010920 <--
	HU 2003001180	A2	20040301	HU 2003-1180	20010920 <--
	HU 2003001180	A3	20051128		
	JP 2004509150	T	20040325	JP 2002-528295	20010920 <--
	NZ 524792	A	20040924	NZ 2001-524792	20010920 <--
	CN 1197620	C	20050420	CN 2001-818617	20010920 <--
	AU 2001287908	B2	20050630	AU 2001-287908	20010920 <--
	TW 287453	B	20071001	TW 2001-90123505	20010920 <--
	AT 401097	T	20080815	AT 2001-967535	20010920 <--
	CA 2461056	A1	20030327	CA 2002-2461056	20020918 <--
	WO 2003025003	A2	20030327	WO 2002-EP10592	20020918 <--
	WO 2003025003	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002362368	A1	20030401	AU 2002-362368	20020918 <--
	AU 2002362368	B2	20060921		
	EP 1427826	A2	20040616	EP 2002-798748	20020918 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR	2002012619	A	20040817	BR	2002-12619	20020918	<--
HU	2004002259	A2	20050128	HU	2004-2259	20020918	<--
CN	1606624	A	20050413	CN	2002-823087	20020918	<--
CN	100392085	C	20080604				
JP	2005511019	T	20050428	JP	2003-528849	20020918	<--
NZ	531814	A	20051028	NZ	2002-531814	20020918	<--
CN	101255434	A	20080903	CN	2008-10090890	20020918	<--
NO	2003001274	A	20030519	NO	2003-1274	20030319	<--
MX	2003PA02453	A	20030619	MX	2003-PA2453	20030319	<--
ZA	2003002231	A	20040505	ZA	2003-2231	20030320	<--
IN	2003DN00419	A	20070302	IN	2003-DN419	20030320	<--
US	20040076633	A1	20040422	US	2003-380981	20030923	<--
ZA	2004002189	A	20050429	ZA	2004-2189	20040318	<--
NO	2004001157	A	20040519	NO	2004-1157	20040319	<--
MX	2004PA02631	A	20040708	MX	2004-PA2631	20040319	<--
IN	2004KN00369	A	20060217	IN	2004-KN369	20040319	<--
US	20070015721	A1	20070118	US	2004-490011	20041025	<--
IN	2007KN02170	A	20080801	IN	2007-KN2170	20070613	<--
US	20070248614	A1	20071025	US	2007-764814	20070619	<--
PRAI	GB 2000-23008	A	20000920				<--
	WO 2001-GB4207	W	20010920				<--
	GB 2001-29604	A	20011211				<--
	GB 2002-6462	A	20020319				<--
	CN 2002-823087	A3	20020918				<--
	WO 2002-EP10592	W	20020918				<--
	US 2003-380981	A1	20030923				<--
	IN 2004-KN369	A3	20040319				

OS MARPAT 136:261816

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT